Information about POMALYST + dexamethasone + daratumumab and hyaluronidase-fihj does not appear in the POMALYST Prescribing Information (PI). Please see the daratumumab and hyaluronidase-fihj full PI for a complete discussion of Important Safety Information at www.darzalexhcp.com/faspro.

Daratumumab and hyaluronidase-fihj is indicated for the treatment of adult patients with multiple myeloma in combination with POMALYST and dexamethasone in patients who have received at least one prior line of therapy including lenalidomide and a proteasome inhibitor.

Limitations of Use:
Daratumumab and hyaluronidase-fihj is not indicated and is not recommended for the treatment of patients with light chain (AL) amyloidosis who have NYHA Class IIIB or Class IV cardiac disease or Mayo Stage IIIB outside of controlled clinical trials.